

## Clinical Quality Measures

2023 measurement year

| Measure   |                         | Rating         | Rate   |
|---|-------------------------|----------------|--------|
| Adolescent Depression                                 | PHQ-9 Utilization*      | Above          | 96.80% |
|   | Follow-up at Six Months | Expected       | 40.00% |
|   | Response at Six Months  | Expected       | 16.20% |
|   | Remission at Six Months | Expected       | 8.60%  |
|   | Follow-up at 12 Months  | Expected       | 37.10% |
|   | Response at 12 Months   | Expected       | 12.40% |
|   | Remission at 12 Months  | Expected       | 6.70%  |
| Adult Depression                                      | PHQ-9 Utilization*      | Above          | 93.20% |
|   | Follow-up at Six Months | Below Expected | 25.00% |
|   | Response at Six Months  | Expected       | 10.00% |
|   | Remission at Six Months | Expected       | 7.50%  |
|   | Follow-up at 12 Months  | Expected       | 25.00% |
|   | Response at 12 Months   | Expected       | 7.50%  |
|   | Remission at 12 Months  | Expected       | 2.50%  |
| Adolescent Mental Health and/or Depression Screening* |                         | Above          | 98.90% |
| Colorectal Cancer Screening                           |                         | -              | -      |
| Optimal Asthma Control - Adults                       |                         | Above Expected | 83.60% |
| Optimal Asthma Control - Children                     |                         | Above Expected | 83.60% |
| Optimal Diabetes Care                                 |                         | -              | -      |
| HbA1c Control   |                         | -              | -      |
| BP Control  |                         | -              | -      |
| Daily Aspirin Use                                     |                         | -              | -      |
| Statin Use  |                         | -              | -      |
| Tobacco-Free  |                         | -              | -      |
| Optimal Vascular Care                                 |                         | -              | -      |
| BP Control  |                         | -              | -      |
| Daily Aspirin Use                                     |                         | -              | -      |
| Statin Use  |                         | -              | -      |
| Tobacco-Free  |                         | -              | -      |

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

\*Measure not risk adjusted

## Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

| Measure   | Rating  | Rate   |
|---|---------|--------|
| Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis | Above   | 86.50% |
| Breast Cancer Screening   | -       | -      |
| Cervical Cancer Screening   | -       | -      |
| Childhood Immunization Status (Combo 10)                            | Above   | 64.70% |
| Chlamydia Screening in Women  | Below   | 30.80% |
| Controlling High Blood Pressure                                     | -       | -      |
| Diabetes Eye Exam   | -       | -      |
| Immunizations for Adolescents (Combo 2)                             | Average | 45.20% |
| Follow-up Care for Children Prescribed ADHD Medication              | Average | 44.60% |
| Osteoporosis Management in Women Who Had a Fracture                 | -       | -      |
| Use of Spirometry Testing in the Assessment and Diagnosis of COPD   | -       | -      |

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

### Ratings

**Above:** Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

**Average:** Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

**Below:** Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

## Total Cost of Care

2023 measurement year

| Population | Monthly Average Cost | Rating             | Higher/Lower than Average |
|------------|----------------------|--------------------|---------------------------|
| Overall    | \$632                | Lower than average | -10.80%                   |
| Adults     | -                    | -                  | -                         |
| Pediatric  | \$312                | Lower than average | -8.60%                    |